Patents by Inventor Bruce McCreedy, JR.

Bruce McCreedy, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11944680
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: April 2, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230277659
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 18, 2023
    Publication date: September 7, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, JR.
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11628218
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: April 18, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220152199
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Inventors: Daniel GETTS, Yuxiao Wang, Bruce McCreedy, JR.